TITLE

Missing the target?

AUTHOR(S)
Lee, Jaimy
PUB. DATE
March 2013
SOURCE
Modern Healthcare;3/18/2013, Vol. 43 Issue 11, p38
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses recent developments in personalized medicine, an approach that is hoped to radically change cancer treatment. It notes that despite the U.S. Food and Drug Administration's approval of several new drugs with companion diagnostics, the new targeted therapies do not seem to live up to their promise. According to the author, questions about whether more targeted therapies will, in fact, bend the cost curve and improve outcomes for patients with cancer remain unanswered.
ACCESSION #
86217606

 

Related Articles

  • Missing the target? Lee, Jaimy // Modern Healthcare;3/18/2013, Vol. 43 Issue 11, p38 

    The article discusses recent developments in personalized medicine, an approach that is hoped to radically change cancer treatment. It notes that despite the U.S. Food and Drug Administration's approval of several new drugs with companion diagnostics, the new targeted therapies do not seem to...

  • Targeting your melanoma therapy. Gagnon, Louise // Dermatology Times;May2015, Vol. 36 Issue 5, p1 

    The article reports on the statements issued by Charles M. Balch of the University of Texas Southwestern Medical Centers in Dallas, Texas which held that personalized therapy in cancer management will likely to continue as more clues about the genetic and molecular signature of melanomas are...

  • Dabrafenib: First Global Approval. Ballantyne, Anita; Garnock-Jones, Karly // Drugs;2013, Vol. 73 Issue 12, p1367 

    Dabrafenib (Tafinlar®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's research programme for the discovery of selective inhibitors of mutant BRAF kinase activity, for the treatment of solid tumours; mutations in the BRAF gene are associated with increased growth and...

  • DRUG APPROVED TO TREAT RARE FORM OF CYSTIC FIBROSIS.  // Contemporary Pediatrics;Feb2012, Vol. 29 Issue 2, p10 

    The article reports that the U.S. FDA has approved the drug ivacaftor for use in patients with cystic fibrosis (CF) aged 6 years or above who have the G551D mutation in the CF transmembrane regulator (CFTR) gene.

  • Pembrolizumab: First Global Approval. Poole, Raewyn // Drugs;Oct2014, Vol. 74 Issue 16, p1973 

    Pembrolizumab [Keytruda (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic...

  • OSI Pharmaceuticals announces Tarceva launch.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p6 

    Reports that OSI Pharmaceuticals Inc. has launched its anticancer agent Tarceva for the treatment of nonsmall cell lung cancer after the approval of the drug by the United States Food and Drug Administration. Wholesale price of the drug per 30-day supply; Two strengths of the drug; Reason why...

  • Bevacizumab approved for lung cancer.  // WHO Drug Information;2006, Vol. 20 Issue 4, p271 

    The article reports that the U.S. Food and Drug Administration has approved use of bevacizumab in combination with carboplatin and paclitaxel for initial systemic treatment of patients with lung cancer. Approval was based on an improvement in survival time of the patient. The most serious...

  • U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia. Alvandi, Firoozeh; Kwitkowski, Virginia E.; Ko, Chia‐Wen; Rothmann, Mark D.; Ricci, Stacey; Saber, Haleh; Ghosh, Debasis; Brown, Janice; Pfeiler, Erika; Chikhale, Elsbeth; Grillo, Joseph; Bullock, Julie; Kane, Robert; Kaminskas, Edvardas; Farrell, Ann T.; Pazdur, Richard // Oncologist;2014, Vol. 19 Issue 1, p94 

    On October 26, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval to omacetaxine mepesuccinate (Synribo; Teva Pharmaceuticals USA, Inc., North Wales, PA, http://www.tevausa.com) for the treatment of adult patients with chronic phase (CP) or accelerated phase (AP)...

  • Cancer drugs find a companion with new diagnostic tests. Schubert, Charlotte // Nature Medicine;Oct2011, Vol. 17 Issue 10, p1157 

    The article focuses on the approach of pharmaceutical companies for companion diagnostics in cancer drugs. It states that the patient populations are divided into smaller groups, wherein the drugmakers threatened to contract and not to expand their markets. It mentions that the approval of the...

  • Pharmacyclics Re-Files Xcytrin NDA With FDA.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p3 

    The article reports on the filing of a new drug application for Xcytrin in combination with standard radiation therapy for non-small-cell lung cancer patients with brain metastasis by Pharmacyclics Inc. Despite a prior refusal from U.S. Food and Drug Administration, the company believes that the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics